\"Attention Deficit Hyperactivity Disorder\" | Identifying Characteristic Signature of Attention Deficit / Hyperactivity Disorder (ADHD) and Ritalin Treatment

\"Attention Deficit Hyperactivity Disorder\" research study

What is the primary objective of this study?

In this study we try to identify the signature of brain activity in the EEG of attention deficit disorder (ADHD) patients compared to healthy subjects under different doses of Ritalin (methylphenidate) treatment.

Who is eligible to participate?

Inclusion Criteria: - Healthy subjects, aged 18-50 years. - Subjects aged 18-50 years diagnosed with ADHD and treated with Ritalin regularly (at least once a week). Exclusion Criteria: - Patients previously diagnosed as suffering from a brain disease except for ADHD. - Patients after traumatic head injury. - Patients who are unable to express their consent to participate in the study.

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

\"Attention Deficit Hyperactivity Disorder\"

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:RitalinPatients with ADHD and healthy subjects will be examined under Ritalin or placebo


Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

RitalinRitalin treatment at different doses

PlaceboTwo meetings, one of which will be given a placebo and the other will be given a low dose of Ritalin, randomly.

Study Status

Unknown status

Start Date: October 2013

Completed Date: December 2015

Phase: N/A

Type: Interventional


Primary Outcome: Resting oscillation activity and Event-related-Potentials in Attention Deficit / Hyperactivity Disorder (ADHD) and healthy subjects.

Secondary Outcome:

Study sponsors, principal investigator, and references

Principal Investigator: Renana Eitan, MD

Lead Sponsor: Hadassah Medical Organization


More information:

Discuss Concerta